Jan 12 (Reuters) - Revvity said on Monday it expects its 2025 adjusted profit per share to exceed its forecast of $4.90 to $5, as the medical equipment maker benefits from renewed demand for contract research and diagnostics services.
The company's shares were up nearly 6% in extended trading.
Pharmaceutical companies have ramped up drug development in the U.S. amid evolving trade policies under President Donald Trump.
Revvity said it expects to report fourth-quarter revenue of around $772 million, above Wall Street estimates of $760.3 million, according to data compiled by LSEG.
It also expects annual revenue to grow 4% to $2.86 billion, above estimates of $2.84 billion.
The company will report its fourth-quarter and full year 2025 results on February 2.
(Reporting by Puyaan Singh in Bengaluru; Editing by Leroy Leo)
LATEST POSTS
- 1
Why this Iranian island looks like Mars after it rains - 2Von der Leyen: Paris meeting sends signal of unity for Ukraine
- 3Judge approves Purdue Pharma’s new $7B opioid settlement with the Sacklers
- 4Here are 10 stores where you can get a free Thanksgiving turkey
- 5Could the Star of Bethlehem have actually been a comet?
- Was This Driver Simply Having A great time Or Behaving Like An Ass?
- The most effective method to Pick A Trade-in vehicle Stage
- 6 Solid Vehicle Fix Administrations to Keep Your Vehicle in Prime Condition
- The most effective method to Succeed in Your Web based Advertising Degree: Procedures for Progress
- 6 Solid Moving Administrations for a Calm Movement
- Deadly heat worldwide prompts $300 million for climate health research at COP30
- An eye for an eye: People agree about the values of body parts across cultures and eras
- Reality TV star Spencer Pratt, who lost his home in Palisades Fire, is running for mayor of Los Angeles
- Philippines evacuates 3,000 villagers after volcano activity raises alert level
